Background: Triple-negative breast cancers (TNBC) are aggressive tumours with limited treatment options and poor prognosis. Gene expression profiling is the gold standard for subtyping, but its limited availability in resource-constrained settings underscores the need for pragmatic approaches such as immunohistochemistry (IHC). This study aimed to classify TNBC into molecular subtypes using IHC markers and to evaluate the prognostic role of tumour-infiltrating lymphocytes (TILs) and immune markers in an Indian cohort.Materials and Methods: We retrospectively analysed 100 TNBC cases (2017–2021). Subtyping was performed using surrogate IHC markers for Basal, Luminal Androgen Receptor (LAR), Mesenchymal, Mixed, and Unclassified phenotypes. Stromal TILs were quantified and categorized as low (40%). Expression of immune markers (CD8, CD20, FOXP3) was evaluated, and survival outcomes were assessed using Kaplan–Meier analysis.Results: The cohort showed a predominance of Basal subtype (37%), followed by LAR (15%), Mixed (20%), Unclassified (25%), and Mesenchymal (3%). High stromal TILs (>40%) were significantly associated with improved disease-free survival (DFS) and overall survival (OS) (p < 0.05). Intra and peritumoral TIL distribution conferred the best prognosis, whereas desert-type infiltration predicted poor outcomes. Low CD8 expression and reduced CD8/FOXP3 ratio correlated with higher recurrence risk. Among 27 patients receiving neoadjuvant chemotherapy, higher TIL density predicted better pathological response.Conclusion: IHC-based subtyping, coupled with immune microenvironment assessment, provides valuable prognostic insights and a practical alternative to gene expression profiling in TNBC. This emphasize the integration of IHC-driven classification into routine diagnostics to enhance personalized management strategies in Indian patients.